Variables | HCC | ICC | p value |
---|---|---|---|
Development set | |||
N | 202 | 146 | |
Age (years) | 54.3 ± 9.4 | 57.7 ± 9.3 | 0.001 |
BMI (kg/m2) | 24.2 ± 3.0 | 24.4 ± 3.7 | 0.487 |
Sex (Male, %) | 163 (80.7) | 87 (59.6) | < 0.001 |
HBsAg (%) | 157 (77.7) | 40 (27.4) | < 0.001 |
Hepatitis C (%) | 17 (8.4) | 2 (1.4) | 0.004 |
Cirrhosis (%) | 167 (82.7) | 36 (24.5) | < 0.001 |
Tumor number (Multiple, %) | 36 (17.8) | 7 (4.8) | < 0.001 |
The largest nodule diameter (cm) | 4.9 ± 3.3 | 6.0 ± 2.7 | 0.002 |
Capsule (Incomplete, %) | 11 (5.4) | 17 (11.6) | 0.036 |
WBC (× 109/L) | 5.46 ± 1.92 | 6.84 ± 2.04 | < 0.001 |
Haemoglobin (g/L) | 142.5 ± 14.5 | 136.8 ± 17.2 | 0.001 |
Platelet count (× 109/L) | 166.1 ± 98.5 | 209.1 ± 79.0 | < 0.001 |
MPV (fL) | 10.9 ± 1.3 | 9.9 ± 1.5 | < 0.001 |
PDW (%) | 14.3 ± 2.5 | 14.8 ± 2.5 | 0.032 |
AST (U/L) | 33 (24–45) | 27 (20–40) | 0.002 |
ALT (U/L) | 33 (21–49) | 26 (17–47) | 0.036 |
γ-GGT (U/L) | 58 (33–104) | 80 (36–185) | 0.002 |
Total bilirubin (μmol/L) | 15.3 (11.8–20.1) | 13.5 (10.2–16.8) | 0.001 |
AFP (ng/mL) | 19.4 (4.4–425.0) | 3.2 (1.87–6.07) | < 0.001 |
CA19-9 (U/mL) | 16.4 (9.5–31.1) | 44.2 (20.2–470.2) | < 0.001 |
FIB-4 | 2.1 (1.4–3.2) | 1.5 (1.1–2.4) | < 0.001 |
APRI | 0.5 (0.3–1.0) | 0.4 (0.2–0.6) | < 0.001 |
NLR | 1.99 ± 1.36 | 3.58 ± 1.75 | 0.001 |
Validation set | |||
N | 107 | 51 | |
Age (years) | 52.7 ± 10.2 | 58.8 ± 9.6 | < 0.001 |
BMI (kg/m2) | 22.0 ± 2.6 | 22.7 ± 2.3 | 0.082 |
Sex (male, %) | 80 (74.8) | 22 (43.1) | < 0.001 |
HBsAg (%) | 63 (58.9) | 11 (21.6) | < 0.001 |
Hepatitis C (%) | 1 (0.9) | 3 (5.9) | 0.064 |
Cirrhosis (%) | 50 (46.7) | 16 (31.4) | 0.067 |
Tumor number (Multiple, %) | 18 (16.8) | 5 (9.8) | 0.242 |
The largest nodule diameter (cm) | 6.4 ± 4.2 | 6.8 ± 5.6 | 0.636 |
Capsule (Incomplete, %) | 32 (29.9) | 25 (49.0) | 0.019 |
WBC (× 109/L) | 8.14 ± 3.58 | 8.75 ± 5.00 | 0.382 |
Haemoglobin (g/L) | 121.8 ± 23.7 | 130.8 ± 18.7 | 0.018 |
Platelet count (× 109/L) | 178.2 ± 91.5 | 252.3 ± 98.8 | < 0.001 |
MPV (fL) | 11.2 ± 1.0 | 10.3 ± 0.9 | < 0.001 |
PDW (%) | 13.2 ± 2.2 | 13.5 ± 2.0 | 0.431 |
AST (U/L) | 38 (26–61) | 55 (25–122) | 0.062 |
ALT (U/L) | 50 (30–87) | 93 (27–169) | 0.058 |
γ-GGT (U/L) | 78 (42–137) | 158 (66–413) | < 0.001 |
Total bilirubin (μmol/L) | 18.2 (14.0–25.4) | 47.0 (16.5–137.1) | < 0.001 |
AFP (ng/mL) | 23.7 (4.7–482.4) | 2.8 (1.6–3.7) | < 0.001 |
CA19-9 (U/mL) | 16.7 (6.8–32.1) | 96.6 (28.8–285.7) | < 0.001 |
FIB-4 | 2.0 (1.1–3.3) | 1.6 (1.0–2.8) | < 0.001 |
APRI | 0.7 (0.3–1.2) | 0.7 (0.3–1.4) | 0.132 |
NLR | 3.96 ± 1.76 | 4.17 ± 1.32 | 0.548 |